Niels van de Donk, MD, PhD, on Early Results on Teclistamab as a Future Treatment Option for Multiple Myeloma

Posted: Thursday, June 24, 2021

Niels van de Donk, MD, PhD, of Amsterdam University Medical Center, discusses updated phase I results on teclistamab, an antibody that binds to both the B-cell maturation antigen and CD3. The agent seemed to be well tolerated and demonstrated encouraging efficacy with durable, deepening responses, warranting further investigation as monotherapy and in combination with other agents.